Abstract:
2,3-Dihydroxybenzoic acid derivatives, a preparation method thereof, and a skin-whitening cosmetic composition containing the same compounds are provided to inhibit activity of tyrosinase and melanin formation while cytotoxicity of the compounds is very low, so that the compounds are useful for improvement of pigmentation in the skin. The method for preparing the 2,3-dihydroxybenzoic acid derivatives represented by the formula(1) comprises the steps of: (A) reacting 2,3-dihydroxybenzoic acid with acetic acid anhydride in the presence of base to prepare a 2,3-diacetyloxybenzoic acid compound represented by the formula(2); (B) preparing an amide compound represented by the formula(3) from the 2,3-diacetyloxybenzoic acid compound by using ethylchloroformate and amine having a lipophilic group; and (C) hydrolyzing an acetyl group of the amide compound represented by formula (3) to prepare 2,3-dihydroxybenzoic acid represented by the formula (1), wherein R is 4-ethoxyphenyl, 2-cyclohexenylethyl, cycloheptyl, cyclohexyl, tert-octyl, 4-isopropylphenyl, 2,3-dihydrobenzo[1,4]dioxin-7-yl, benzo[1,3]-dioxol-6-yl or adamantyl-1-yl; and the amine having the lipophilic group is an amine selected from 4-ethoxyphenylamine, 2-cyclohexenylethylamine, cycloheptylamine, cyclohexylamine, tert-octylamine, 4-isopropylphenylamine, 2,3-dihydrobenzo[1,4]dioxin-7-amine, benzo[1,3]-dioxol-6-amine or adamantyl-1-amine. The skin-whitening cosmetic composition contains 0.01-20 wt.% of the 2,3-dihydroxybenzoic acid derivatives represented by the formula(1).
Abstract:
Sesamol derivatives or their salts, a process for preparing the same compounds, and a skin external composition containing the same compounds are provided to prevent aging of the biological membrane by slowly releasing sesamol and 3-aminopropan phosphate, and reduce the skin irritation. The sesamol derivatives represented by the formula(I) or their salts are provided, wherein the salt is alkali metal salt or alkali earth metal salt. The process for preparing the sesamol derivatives represented by the formula(I) or their salts comprises the steps of: (A) reacting sesamol with phosphorus oxychloride in the presence of organic base at 12-18 deg. C for 1-2 hours to prepare dichloro[3,4-methylene dioxy penoxy]-phosphino-1-one; (B) reacting the dichloro[3,4-methylene dioxy penoxy]-phosphino-1-one with organic solvent in the presence of base to prepare [3,4-methylene dioxy penoxy]-1,3,2-oxazaphosphorin P-oxide; (C) after filtering the reaction solution and concentrating the filtered solution under reduced pressure, adding the acid solution into the concentrate and reacting them at 5-100 deg. C for 3-12 hours to prepare sesamol(3-aminopropane phosphate diester); and (D) crystallizing the sesamol(3-aminopropane phosphate diester) by slowly dropping polar organic solvent into the sesamol.
Abstract:
본발명은약물을내포하는생체적합성양친성블록공중합체로이루어진것을특징으로하는, 자가조립나노입자방출형용해성마이크로니들구조체및 이의제조방법에관한것이다. 본발명의마이크로니들구조체는수용성또는소수성약물을마이크로니들에내포시켜전달할수 있으며, 특히지용성약물은구조체의용해와함께형성되는미셀형태의자기조립나노입자내에담지되어전달되므로, 수용액상의용해도를크게높일수 있어, 기존의흡수가용이하지않았던약물을피부를통해체내로전달할수 있다.